Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature.

Extensive research has been conducted on multiple methods for manufacturing Nintedanib and its formulations. This dynamic study has the potential to create opportunities for numerous generic companies to enter the United States market. This, in turn, will improve healthcare accessibility by lowering costs.